UBS Group
ACXP icon

UBS Group’s Acurx Pharmaceuticals ACXP Stock Holding History

UBS Group’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.4K Buy
6,312
+6,143
+3,635% +$17.4K ﹤0.01% 7827
2025
Q4 		$420 Buy
+169
New +$810 ﹤0.01% 9975
2025
Q3 		– Sell
-1,938
Closed -$19.8K – 10286
2025
Q2 		$19.8K Buy
1,938
+1,936
+96,800% +$15.6K ﹤0.01% 8450
2025
Q1 		$18 Sell
2
-296
-99% -$3.99K ﹤0.01% 10098
2024
Q4 		$4.85K Buy
+298
New +$8.97K ﹤0.01% 8719
2024
Q3 		– Sell
-44
Closed -$1.98K – 9444
2024
Q2 		$1.98K Buy
+44
New +$1.93K ﹤0.01% 8447
2023
Q2 		– Sell
-145
Closed -$10K – 8823
2023
Q1 		$10K Buy
145
+8
+6% +$583 ﹤0.01% 7612
2022
Q4 		$10.9K Sell
137
-67
-33% -$4.41K ﹤0.01% 8463
2022
Q3 		$12K Buy
204
+152
+292% +$11.4K ﹤0.01% 8135
2022
Q2 		$4K Buy
+52
New +$3.5K ﹤0.01% 9025

Other funds holding ACXP

Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.33B AUM 24% 1-Year Est. Return

UBS Group's ACXP Position: Q1 2026 in Review

UBS Group increased its Acurx Pharmaceuticals (ACXP) stake by 3,635% in Q1 2026, buying an estimated $17.4K and bringing the position to 6,312 shares worth $23.4K. The position accounts for ﹤0.01% of the portfolio, ranked #7827.

UBS Group first reported a position in ACXP in Q2 2022 and has held it in 10 quarters since. 21 funds tracked by Wall St. Rank hold ACXP as of Q1 2026.

  • UBS Group held 6,312 shares of Acurx Pharmaceuticals worth $23.4K as of Q1 2026.
  • UBS Group bought 6,143 Acurx Pharmaceuticals shares in Q1 2026, an estimated $17.4K.
  • Acurx Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7827 holding.
  • UBS Group first reported a position in Acurx Pharmaceuticals in Q2 2022 and has held it in 10 quarters since.
  • 21 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.